PROMISE I – U.S. Feasibility Study


PROMISE I is a multi-center, prospective, single-arm study conducted at seven U.S. centers encompassing end-stage — or “no option” — CLTI patients. All patients were confirmed as “No-Option” and facing imminent amputation by an independent review committee of vascular surgeons. Patients were enrolled between July 2017 and April 2019.

Patient Demographics

32 Patients

PROMISE I - Demographics | amCharts

PROMISE I Study Results - U.S.
Rutherford class 5 or 6
Ineligible for endovascular or surgical procedures to restore blood flow

12-Month Outcomes1


PROMISE I - Primary Endpoint Amputation Free Survival | amCharts

Freedom from Amputation
Amputation-free survival
Technical success

Watch interview with PROMISE I PI Dan Clair, MD

1. Clair, Dan. “Results of the LimFlow System in the Promise I Trial” Vascular Interventional Advances Conference”. November 2019, The Wynn Las Vegas. Late Breaking Clinical Trial Presentation.

LimFlow, Inc.
3031 Tisch Way
110 Plaza West
San Jose, CA 95128
United States of America
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use.
©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.